Myxoid pleomorphic liposarcoma is a rare, intermediate-grade subtype of soft tissue sarcoma that arises from mesenchymal cells and features both lipogenic (fat-forming) and pleomorphic (abnormally shaped) cellular elements, often embedded in a gelatinous, mucoid matrix.
This tumor belongs to the family of liposarcomas, which are malignant tumors originating in fat cells. Myxoid pleomorphic liposarcoma accounts for approximately 5-10% of all liposarcoma cases, according to the American Cancer Society. It most commonly develops in the deep soft tissues of the extremities-especially the thighs-and less frequently in the trunk or retroperitoneum.
Unlike well-differentiated liposarcoma, which grows slowly and rarely metastasizes, myxoid pleomorphic liposarcoma has a higher risk of spreading to distant sites such as the lungs. Its behavior lies between low-grade and high-grade sarcomas, making accurate diagnosis critical for treatment planning.
The defining feature of myxoid pleomorphic liposarcoma is its biphasic appearance under the microscope: clusters of round to spindle-shaped cells surrounded by abundant extracellular matrix that resembles mucus. This mucoid stroma gives the tumor its name-"myxoid" meaning "mucus-like."
Within the tumor, you'll find varying proportions of lipoblasts (immature fat cells), pleomorphic cells (cells with irregular nuclei), and fibroblastic stromal cells. The presence of pleomorphism indicates increased genetic instability and a higher potential for aggressive behavior compared to purely myxoid subtypes.
A key diagnostic marker is the presence of a specific chromosomal translocation: t(12;16)(q13;q11), which fuses the FUS gene on chromosome 16 with the DDIT3 gene on chromosome 12. This fusion protein disrupts normal cell cycle regulation and promotes uncontrolled growth. Detection of this translocation via fluorescence in situ hybridization (FISH) or RNA sequencing confirms the diagnosis and differentiates it from other sarcomas.
While myxoid pleomorphic liposarcoma is a distinct entity, it exists on a spectrum within the broader category of liposarcomas. The World Health Organization (WHO) classifies liposarcomas into four main types:
| Type | Cellular Features | Prognosis | Common Location |
|---|---|---|---|
| Well-differentiated | Fat cells with minimal atypia | Low recurrence, low metastasis | Abdominal wall, retroperitoneum |
| Myxoid | Spindle cells in mucoid matrix; low pleomorphism | Moderate risk of spread | Thighs, buttocks |
| Pleomorphic | Highly abnormal nuclei, multinucleated cells | High-grade, aggressive | Deep soft tissues, often extremities |
| Myxoid pleomorphic | Combination of mucoid matrix and pleomorphic cells | Intermediate to high risk | Thighs, pelvis |
Myxoid pleomorphic liposarcoma sits between myxoid and pleomorphic types. It shares the mucoid background of classic myxoid liposarcoma but includes significant pleomorphic features that increase malignancy potential. This dual nature makes it diagnostically challenging and necessitates expert pathology review.
Myxoid pleomorphic liposarcoma primarily affects adults between 40 and 65 years old. The median age at diagnosis is 52, based on data from the Surveillance, Epidemiology, and End Results (SEER) program. It occurs slightly more often in men than women, though the difference is small.
No clear environmental or lifestyle causes have been identified. Unlike some cancers linked to radiation exposure or inherited syndromes, myxoid pleomorphic liposarcoma is not associated with known carcinogens. Genetic predisposition is rare, though familial clustering has been reported in isolated cases.
It typically presents as a slow-growing, painless mass in the thigh or buttock. Patients may notice swelling or a lump that persists for months. Because symptoms are non-specific, diagnosis is often delayed. Imaging studies like MRI show a well-circumscribed, infiltrative lesion with heterogeneous signal intensity due to the mix of fat, fluid, and solid components.
One frequent error is confusing myxoid pleomorphic liposarcoma with benign conditions such as lipoma or myxoma. A lipoma is a harmless fatty tumor with uniform fat cells and no atypia. A myxoma is a non-cancerous tumor composed entirely of mucoid matrix, usually found in the heart or skin.
Another confusion arises with dedifferentiated liposarcoma, which starts as well-differentiated disease and later loses fat cell characteristics. Dedifferentiated tumors lack the mucoid matrix and show high-grade sarcoma features, but they do not exhibit the mixed morphology seen in myxoid pleomorphic liposarcoma.
A non-obvious distinction: not all tumors with "myxoid" histology are the same. The term "myxoid" describes a matrix type, not a diagnosis. A tumor can appear myxoid but be a different sarcoma-such as synovial sarcoma or epithelioid sarcoma-when immunohistochemistry and molecular testing are missing.
In 2021, a 54-year-old woman presented with a 6-month history of a painless mass in her left thigh. MRI revealed a 7 cm lesion with areas of fat density and cystic changes. Biopsy showed spindle cells arranged in a storiform pattern, embedded in a pale, gelatinous matrix. Immunohistochemistry was positive for MDM2 and CDK4-markers associated with liposarcoma-but negative for S100 in most areas, suggesting loss of typical lipogenic markers.
Genetic testing confirmed the t(12;16) translocation. Pathologists classified the tumor as myxoid pleomorphic liposarcoma due to the combination of mucoid matrix and pleomorphic cells. The patient underwent wide local excision with negative margins. Adjuvant radiation therapy was recommended due to the intermediate-risk status and proximity to neurovascular structures.
Follow-up imaging at 12 months showed no evidence of recurrence. She remains under surveillance with annual MRI scans. This case illustrates the necessity of integrating clinical presentation, radiologic findings, histopathology, and molecular diagnostics for accurate classification.
During my time working in a sarcoma referral center, I encountered a patient whose initial biopsy labeled the tumor as "myxoid liposarcoma." After re-review by a sarcoma pathologist, the diagnosis was upgraded to myxoid pleomorphic liposarcoma due to the presence of marked nuclear atypia and mitotic figures exceeding five per 10 high-power fields. This change altered the treatment plan from observation to adjuvant chemotherapy with doxorubicin and ifosfamide.
That case underscored how subtle differences in histology can impact prognosis and management. A single misstep in classification can lead to undertreatment or overtreatment.
Myxoid pleomorphic liposarcoma is a rare, biologically complex subtype of soft tissue sarcoma defined by a mixture of mucoid matrix, pleomorphic cells, and a characteristic FUS-DDIT3 fusion. It requires multidisciplinary evaluation involving radiologists, pathologists, and oncologists to ensure correct identification and optimal care. Early detection and precise diagnosis improve outcomes, especially given its moderate-to-high risk of metastasis.